Harm avoidance dimension of the Tridimensional Personality Questionnaire and serotonin-1A activity in depressed patients.
Hansenne
M
M
Psychiatric Unit, CHU du Sart Tilman B-35, Liège, Belgium.
Pitchot
W
W
Moreno
A G
AG
Reggers
J
J
Machurot
P Y
PY
Ansseau
M
M
D000328:Adult; D003866:Depressive Disorder / Q000097:blood / Q000150:complications / Q000175:diagnosis*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010554:Personality Disorders / Q000150:complications / Q000175:diagnosis*; D010879:Piperazines / Q000008:administration & dosage / Q000494:pharmacology*; D011388:Prolactin / Q000097:blood / Q000378:metabolism; D011863:Radioimmunoassay / Q000379:methods; D012701:Serotonin / Q000097:blood / Q000378:metabolism*; D017366:Serotonin Receptor Agonists / Q000008:administration & dosage / Q000494:pharmacology*; D011795:Surveys and Questionnaires
D010879:Piperazines; D017366:Serotonin Receptor Agonists; D012701:Serotonin; C056895:flesinoxan; D011388:Prolactin